跳转到内容

匹莫范色林

维基百科,自由的百科全书
匹莫范色林
临床资料
商品名英语Drug nomenclatureNuplazid
其他名称ACP-103; BVF-036; BVF-048
核准状况
给药途径By mouth
药物类别英语Drug classAtypical antipsychotic
ATC码
法律规范状态
法律规范
药物动力学数据
血浆蛋白结合率94–97%[2]
药物代谢Hepatic (CYP3A4, CYP3A5, CYP2J2)[1]
生物半衰期54–56 hours[2]
识别信息
  • N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl)carbamide
CAS号706779-91-1
706782-28-7 (tartrate))  checkY
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard英语CompTox Chemicals Dashboard (EPA)
化学信息
化学式C25H34FN3O2
摩尔质量427.56 g·mol−1
3D模型(JSmol英语JSmol
  • CC(C)COc3ccc(cc3)CNC(=O)N(C(CC2)CCN2C)Cc(cc1)ccc1F
  • InChI=1S/C25H34FN3O2/c1-19(2)18-31-24-10-6-20(7-11-24)16-27-25(30)29(23-12-14-28(3)15-13-23)17-21-4-8-22(26)9-5-21/h4-11,19,23H,12-18H2,1-3H3,(H,27,30) ☒N
  • Key:RKEWSXXUOLRFBX-UHFFFAOYSA-N ☒N

匹莫范色林(英语:Pimavanserin,商品名:Nuplazid)是一种非典型抗精神病药物,被批准用于治疗帕金森氏病,也正在研究用于治疗阿尔茨海默病精神病、精神分裂症、躁动和重度抑郁症。[3] 与其他抗精神病药不同,匹莫范色林不是多巴胺受体拮抗剂。[4]

它被批准为仿制药。[5]

参考文献

  1. ^ 1.0 1.1 Nuplazid- pimavanserin tartrate capsule Nuplazid- pimavanserin tartrate tablet, coated. DailyMed. 21 December 2022 [12 March 2023]. 
  2. ^ 2.0 2.1 Friedman JH. Pimavanserin for the treatment of Parkinson's disease psychosis. Expert Opinion on Pharmacotherapy. October 2013, 14 (14): 1969–75. PMID 24016069. S2CID 35649566. doi:10.1517/14656566.2013.819345. 
  3. ^ Pimavanserin - ACADIA Pharmaceuticals - AdisInsight. adisinsight.springer.com. [2024-07-10]. 
  4. ^ Howland, Robert H. Pimavanserin: An Inverse Agonist Antipsychotic Drug. Journal of Psychosocial Nursing and Mental Health Services. 2016-06, 54 (6). ISSN 0279-3695. doi:10.3928/02793695-20160523-01 (英语). 
  5. ^ Research, Center for Drug Evaluation and. First Generic Drug Approvals. FDA. 2024-07-08 [2024-07-10] (英语). 

外部链接